If mitochondria age in part because their membranes come apart, then one of the most direct ideas in the whole field is simple to state: protect the membrane. SS-31 — known in research as elamipretide — is the compound that took that idea furthest, and in 2025 it did something no mitochondria-targeted therapeutic had done before. It earned an FDA approval.

A peptide with a very specific address

SS-31 is a small, cell-penetrating tetrapeptide, and its defining trick is where it goes. It concentrates in the inner mitochondrial membrane and binds cardiolipin, a distinctive four-tailed lipid found there in abundance and almost nowhere else in the cell. Cardiolipin is not passive scaffolding. It stabilizes the folded architecture of the inner membrane — the cristae — and helps organize the electron transport chain’s protein complexes into the efficient assemblies that produce most of the cell’s ATP.

That is why cardiolipin is such an interesting target. When it is damaged or depleted — by oxidative stress, by aging, or by a genetic defect — the membrane’s folds loosen, the energy machinery loses its organization, electrons leak, and dysfunction compounds. By binding cardiolipin (an interaction driven by the peptide’s strong positive charge meeting the lipid’s negative head groups), SS-31 is proposed to help preserve that architecture: steadier cristae, better-organized respiratory complexes, less electron leak. It is less a stimulant than a structural stabilizer — a molecule thought to help the membrane hold its shape. This membrane-stabilizing mechanism is supported primarily by mechanistic and preclinical evidence, and it is the working model behind the clinical program rather than something a single trial has confirmed in full.

The approval: a genuine first

In September 2025, the FDA granted accelerated approval to elamipretide (brand name Forzinity) to improve muscle strength in patients with Barth syndrome, an ultra-rare, life-limiting genetic disease in which a mutation disrupts cardiolipin itself. It is the first approved treatment for Barth syndrome — and, notably, the first mitochondria-targeted therapeutic the FDA has ever approved.

The evidence base includes TAZPOWER, a placebo-controlled trial followed by a long open-label extension in which patients showed sustained improvements in functional and cardiac measures over 168 weeks. It is worth reading the approval precisely: it is accelerated, granted on an intermediate endpoint (an improvement in knee-extensor muscle strength), which means continued approval depends on confirmatory trials verifying clinical benefit. That is a real and meaningful milestone, and it is a first step rather than a finish line — exactly the kind of distinction worth holding onto.

What the harder trial taught us

The Barth result is more striking because a larger, more general trial had not succeeded. MMPOWER-3 tested subcutaneous elamipretide in 218 adults with primary mitochondrial myopathy — a broader population — and it did not meet its co-primary endpoints: the differences from placebo on a six-minute walk test and a fatigue score were small and not statistically significant. The drug was well tolerated, but on those measures it did not separate from placebo.

That contrast is not a disappointment to explain away; it is informative. Primary mitochondrial myopathy is a genetically heterogeneous condition, and a later analysis of the data suggested that patients whose disease stems from nuclear-gene defects may respond differently than those with mitochondrial-DNA mutations. In other words, which mitochondrial problem a person has may shape whether a membrane-stabilizing peptide helps. Barth syndrome — a disease of cardiolipin specifically — is close to the mechanism’s home turf. The general myopathy population was not. Matching a mechanism to the right biology turns out to be much of the game.

What is still being learned

Beyond Barth syndrome, SS-31 remains genuinely investigational, and the open questions are the interesting ones. Its most enthusiastically discussed potential uses — in heart failure, in age-related muscle and metabolic decline, in the ordinary mitochondrial wear of aging — are supported largely by preclinical work and mechanism, not yet by large positive human trials in those settings. The cardiolipin rationale is elegant and now clinically supported in one rare disease; whether it translates into measurable benefit for common, multifactorial aging is the question the field is actively working to answer.

That is the honest and, frankly, the exciting frame. SS-31 has crossed a threshold no mitochondrial peptide had crossed before, providing the first approved clinical evidence that a mitochondria-targeted treatment can improve a measured outcome in a specific disease. How far that principle extends — and how much of the membrane-stabilization story it ultimately confirms — is now an empirical question with a real answer coming, which is precisely what makes it worth following.

Why it matters

SS-31 represents a distinct strategy in mitochondrial medicine: not fueling the machinery or signaling to it, but physically protecting the structure it depends on. Its approval for Barth syndrome is a landmark — the first FDA approval for a therapy specifically designed to target mitochondrial biology. Reading it accurately means celebrating that genuinely, while keeping clear sight of the line between an approved rare-disease therapy and the broader anti-aging promise still being tested. Both parts of that story are worth telling, because both are true.